The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
Open accessAbstract
Programmed cell death-1 (PD-1) is an inhibitory coreceptor for T lymphocytes that provides feedback inhibition of T cell activation. Although PD-1’s expression on T cells is known to be activation dependent, the factors that determine the timing, intensity, and duration of PD-1 expression in immune reactions are not fully understood. To address this question, we performed a fine mapping analysis of a conserved 5′-flanking region of the PD-1 gene and identified a putative IFN stimulation response element, which was responsible for PD-1 transcription in the 2B4.11 T cell line. Consistent with this finding, activation by IFN-α enhanced both the induction and maintenance of PD-1 expression on TCR-engaged primary mouse T cells through an association IFN-responsive factor 9 (IRF9) to the IFN stimulation response element. Furthermore, PD-1 expression on Ag-specific CD8+ T cells was augmented by IFN-α in vivo. We propose that strong innate inflammatory responses promote primary T cell activation and their differentiation into effector cells, but also cause an attenuated T cell response in sustained immune reactions, at least partially through type I IFN-mediated PD-1 transcription. Based on this idea, we demonstrate that IFN-α administration in combination with PD-1 blockade in tumor-bearing mice effectively augments the antitumor immunity, and we propose this as a novel and rational approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citationAutoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citationExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Self-citationChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.162 · Cited by 1,157
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Self-citationCoinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857
“The residual expression was due to NFAT4, the third NFAT protein present in immune cells: NFAT1,2-deficient cells additionally transduced with shRNA against NFAT4 (Figure 5B) produced little or no IL-2 or interferon-g (IFN-g) upon restimulation (Figure 5A) and expressed little or no LAG3 and PD-1 either under resting…”
InfluentialA pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
Qian, J., Olbrecht, S., Boeckx, B., Vos, H., Laoui, D., Etlioglu, E., Wauters, E., Pomella, V., Verbandt, S., Busschaert, P., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0355-0 · Cited by 817
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Self-citationThe PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Type I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 500
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 369
Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 351
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & Pasca di Magliano, M. (2017) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 337
Choi, J., Ho, J. H., Pasoto, S. G., Bunin, V., Kim, S. T., Carrasco, S., Borba, E. F., Gonçalves, C. R., Costa, P. R., Kallas, E. G., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39020 · Cited by 326
Ovarian cancer mutational processes drive site-specific immune evasion
Vázquez-García, I., Uhlitz, F., Ceglia, N., Lim, J. L. P., Wu, M., Mohibullah, N., Niyazov, J., Ruiz, A. E. B., Boehm, K. M., Bojilova, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05496-1 · Cited by 324
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Yang, H., Lee, W. S., Kong, S. J., Kim, C. G., Kim, J. H., Chang, S. K., Kim, S., Kim, G., Chon, H. J., & Kim, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125413 · Cited by 313
The Role of PD-1 in Acute and Chronic Infection
Jubel, J. M., Barbati, Z. R., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00487 · Cited by 307
The interaction of innate immune and adaptive immune system
Wang, R., Lan, C., Benlagha, K., Camara, N. O. S., Miller, H., Kubo, M., Heegaard, S., Lee, P., Yang, L., Forsman, H., et al. (2024) · MedComm · doi:10.1002/mco2.714 · Cited by 305
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Self-citationKurimoto, C., Inaba, H., Ariyasu, H., Iwakura, H., Ueda, Y., Uraki, S., Takeshima, K., Furukawa, Y., Morita, S., Yamamoto, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14363 · Cited by 160
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Franchini, D.-M., Lanvin, O., Tosolini, M., Patras de Campaigno, E., Cammas, A., Péricart, S., Scarlata, C.-M., Lebras, M., Rossi, C., Ligat, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.014 · Cited by 61
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
Metadata
- Authors
- Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03-01
- Volume
- 186
- Issue
- 5
- Pages
- 2772-2779
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1949743561
- Cited by
- 342
- References
- 32
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.